Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:

NCT ID: NCT04193904 Terminated - Pancreatic Cancer Clinical Trials

A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer

Start date: December 20, 2019
Phase: Phase 1
Study type: Interventional

This is a single center, open-label, phase I study to evaluate the safety and preliminary efficacy of MRx0518 with preoperative hypofractionated radiation in 15 patients with resectable pancreatic cancer. Subjects will take MRx0518 daily for one week prior to the start of radiation therapy, throughout radiation and until surgical resection of the tumour.

NCT ID: NCT04131192 Terminated - Pancreatic Cancer Clinical Trials

Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer

Start date: November 11, 2019
Phase: Phase 1
Study type: Interventional

This phase IB trial is studying how well giving gemcitabine together with Z650 works in treating patients with metastatic or recurrent pancreatic cancer.

NCT ID: NCT04117958 Terminated - Clinical trials for MUC17-positive Solid Tumors

Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers

Start date: January 20, 2020
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of AMG 199 in adult subjects and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

NCT ID: NCT04106167 Terminated - Colorectal Cancer Clinical Trials

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Start date: June 11, 2019
Phase:
Study type: Observational

Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study. The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.

NCT ID: NCT04070313 Terminated - Pancreatic Cancer Clinical Trials

A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan

Start date: July 11, 2019
Phase: Phase 2
Study type: Interventional

To verify the efficacy of S-1 adjuvant chemotherapy in resectable pancreatic cancer. - Primary Endpoint: Relapse-free survival (RFS) - Secondary Endpoints: 2-year survival rate, 2-year relapse-free survival (RFS) rate, safety profile

NCT ID: NCT04046887 Terminated - Pancreatic Cancer Clinical Trials

Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)

Start date: September 11, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the recommended phase 2 dose (RP2D) of the combination of lonsurf, gemcitabine and nab-paclitaxel in Pancreatic ductal adenocarcinoma (PDAC)

NCT ID: NCT03957096 Terminated - Colorectal Cancer Clinical Trials

A Safety Study of SGN-CD47M in Patients With Solid Tumors

Start date: July 17, 2019
Phase: Phase 1
Study type: Interventional

This trial will study SGN-CD47M to find out whether it is an effective treatment for different types of solid tumors and what side effects (unwanted effects) may occur. The study will have two parts. Part A of the study will find out how much SGN-CD47M should be given for treatment and how often. Part B of the study will use the dose found in Part A and look at how safe and effective the treatment is.

NCT ID: NCT03956056 Terminated - Pancreatic Cancer Clinical Trials

Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

Start date: February 13, 2020
Phase: Phase 1
Study type: Interventional

This is a phase 1 open-label study to evaluate the safety and immunogenicity of a neoantigen peptide vaccine strategy in pancreatic cancer patients following surgical resection and adjuvant chemotherapy. The neoantigen peptide vaccines will incorporate prioritized neoantigens and personalized mesothelin epitopes and will be co-administered with poly-ICLC. The hypothesis of this study is that neoantigen peptide vaccines will be safe and capable of generating measurable neoantigen-specific CD4 and CD8 T cell responses.

NCT ID: NCT03878524 Terminated - Anemia Clinical Trials

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Start date: April 1, 2020
Phase: Phase 1
Study type: Interventional

This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.

NCT ID: NCT03859869 Terminated - Clinical trials for Exocrine Pancreatic Insufficiency (EPI)

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

Start date: February 25, 2020
Phase: Phase 4
Study type: Interventional

This is a study in participants with Exocrine Pancreatic Insufficiency (EPI) due to pancreatic cancer. This study will include resected participants who are post pancreatic cancer surgery, and an additional cohort in non-resected participants.